EGFR and non-small cell lung carcinoma: One such success story is the discovery of osimertinib, a third-generation EGFR TKI that targets activating mutations with or without the T790M gatekeeper mutation, which has significant clinical benefit in patients with non–small cell lung cancer (NSCLC) with activating mutations in EGFR (1).